Page 5 - Shimadzu Journal vol.5 Issue1

Insight from Customer

Also, the Shimadzu LCMS-8040 and LCMS-8050 triple quadrupole Finally, could you share any requests that you have with
mass spectrometers in our labs have proven to be extremely reliable respect to analytical and measuring instrument vendors?
instruments for new clinical diagnostic assay development. Shimadzu
has engineered mass spectrometers with ultra-fast acquisition and Our clinical laboratory relies on automated platforms that operate
polarity switching speeds, yet exquisite sensitivity at these ultra-fast with high throughput. Shimadzu mass spectrometers have come a
speeds. This uncompromised solution enables greater assay long way in terms of ease of use. But these analytical instruments
throughput and drastically reduced assay development times. must become even simpler- push-button analyzers with increased
multiplexing and assay-specific software.
What are Shimadzu’s strengths compared to other vendors I recently visited Shimadzu Corporation in Kyoto, Japan, and I was very
(not limited to the instruments)? impressed with your new CLAM-2000 clinical lab automation module.
This is exactly the type of liquid handling/sample preparation
In addition to the aforementioned performance characteristics, we integration that clinical laboratories need. We hope to play a role as a
have found Shimadzu to provide excellent technical and service voice of North American clinical key opinion leaders in the
support. The local support provided by Shimadzu Scientific development of these new platforms, as well as continue our fruitful
Instruments individuals like Alan Brasel, Ricky Ciner, Thomas Russell, clinical research collaborations.
Chris Gilles, Brian Feild and Scott Kuzdzal have kept our labs
operating at peak efficiency.
It was significant to know what you think of us and our
collaboration. We will strive to meet your request more
Also, while Shimadzu has always provided innovative solutions, we than ever. Thank you very much.
have recently seen a new focus on innovation within Shimadzu. I was
a keynote speaker at the Shimadzu Solution Center Grand Opening in
February, 2014, in Columbia, MD. I am excited to see the new
Innovation Center that is also being developed at SSI. With a great
influx of talented engineers like Hikaru Shibata and Tairo Ogura at SSI,
we see a bright future for Shimadzu and new, innovative platforms.

Prof. Daniel Chan, Drs Hui Zhang and Yuan Tian in front of Dr. Stefani Thomas, Research Associate at the Johns Hopkins School of Medicine
their Shimadzu AXIMA Resonance (2009) in front of the Shimadzu LCMS-8040 triple quadrupole mass spectrometer (2015)

Here are his recent publications:
1. Füzéry AK, Levin J, Chan MM and Chan DW. Translation 4. Serum fucosylated prostate-specific antigen (PSA)
of proteomic biomarkers into FDA approved cancer improves the differentiation of aggressive from
diagnostics: issues and challenges. Clin Proteomics 2013, non-aggressive prostate cancers. Li QK, Chen L, Ao MH,
10:13. Chiu JH, Zhang Z, Zhang H, Chan DW. Theranostics.
2015 Jan 1;5(3):267-76.
2. Sartori DA and Chan DW. Biomarkers in prostate cancer:
what's new? Curr Opin Oncol 2014, 26(3): 259-64. 5. Comprehensive analysis of protein glycosylation by
solid-phase extraction of N-linked glycans and
3. Li, D and Chan DW. Proteomic cancer biomarkers from
glycosite-containing peptides. Sun S, Shah P, Eshghi ST,
discovery to approval: it's worth the effort. Expert Rev
Yang W, Trikannad N, Yang S, Chen L, Aiyetan P, Höti
Proteomics 2014, 11(2):135-6.
N, Zhang Z, Chan DW, Zhang H. Nat Biotechnol. 2016
Jan;34(1):84-8.

5